Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have a great Christmas BLADE.
I'm sure you realize, that if you want to separate yourself from the crowd, you usually have to stand alone.
Your commitment is thought of highly from many on this board.
ZAP Begins Project Development on Green City Partnership with Shanghai’s Yangpu District
Zap (OTCBB:ZAAP)
Intraday Stock Chart
Today : Friday 17 December 2010
Electric car pioneer ZAP (OTCBB:ZAAP) this week began project planning with the government of Shanghai's Yangpu District to develop a Green City Zone in Yangpu's downtown area, a university and research hub that is home to 1.24 million people. Based on an MOU partnership agreement signed in San Francisco on November 19, 2010, the project plans to reduce carbon emissions in Yangpu using electric vehicles (EVs) for its public transportation while installing an EV charging infrastructure, battery swap-out stations and maintenance support centers.
ZAP signed an MOU agreement with the government of Shanghai's Yangpu District on November 19th in San Francisco to provide electric vehicles for public transportation while installing charging and battery swap-out stations. The project was formed during a Bay Area Council trade mission to Shanghai in September. (Photo: Business Wire)
The partnership agreement with Yangpu government is a direct result of Governor Schwarzenegger’s trade delegation to Shanghai in September this year, sponsored by the Bay Area Council, and is one of the first formal initiatives between the two regions.
Party Secretary Chen Yin attended the signing ceremony in San Francisco on November 19, 2010. At the ceremony, Party Secretary Chen said that improving air quality, “green” urban mobility and development of clean energy infrastructure are some of the key initiatives of Yangpu in the next few years. He indicated that this agreement shows the beginning of growing ties between two of the world’s leading technology innovation centers, Yangpu and the Bay Area, especially in the development of clean technology. Within the 24 square mile district of Yangpu there are 14 universities surrounding the Knowledge Innovation Center (KIC), a technology community that includes Fudan University and Tongji University, making this area one of the leading research centers in China on Clean Tech.
“New plug-in vehicle technologies from ZAP, together with Jonway’s cost effective manufacturing in China, will accelerate the implementation of our Green Project with Yangpu. This truly bridges the best aspects of both the US and China, leveraging the strengths of the technological innovation in the Bay Area and Yangpu,” said ZAP CEO Steve Schneider.
According to the framework of the partnership, ZAP will provide an electric car charging infrastructure, battery swap out stations, as well as EV maintenance and repair depots in Yangpu. ZAP will work with Yangpu’s government agencies, local universities, and private corporations on plans to further expand zero-emission transportation in the city.
“We have just started the initial planning of this long term project. The hard work of implementation and operations is ahead of us. We believe that the project planning and resourcing will be a yearlong process. We are pleased to be part of Yangpu’s Green Project and share Party Secretary Chen Yin’s vision and commitment to delivering his objectives,” says ZAP Chairman Dr. Priscilla Lu.
To execute these plans and better access the Chinese market, ZAP Jonway will open its EV sales and operations office in the Yangpu District and plans to establish its research and development engineering center in the district to take advantage of the university communities.
About ZAP
Based in Santa Rosa, ZAP has been a pioneer in the electric vehicle industry since 1994, engaging in the design, development, commercialization and distribution of 100% pure electric vehicles and power systems, and delivering a wide range of vehicle designs to consumers and fleet customers in the United States and international markets for sixteen years. The company supplies electric trucks and vans to military, government and corporate fleets and offers personal transportation products including electric motorcycles, scooters, ATVs and some of the only electric city-speed vehicles in production today. ZAP is also developing a freeway capable electric vehicle called the ZAP Alias that was a finalist in the Progressive Insurance Automotive X PRIZE
MOP Environmental Solutions, Inc. expected to report Fiscal Year 2010 results on March 28, 2011. This event was calculated by Capital IQ (Created on December 6, 2010).
http://www.realpennies.com/otc/MOPN
Excellent Safety and Reproducible Immunogenocity Demonstrated in Early Results of Phase 2a Trial for HIV Preventative Vaccine
ATLANTA, Dec. 9, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), announced today that early results from part A of an ongoing phase 2a clinical trial indicate an excellent safety profile and highly reproducible immunogenicity. The phase 2a trial is testing two recombinant DNA-vectored vaccine inoculations; the first at week 0 and the second at week 8, followed by two recombinant MVA-vectored vaccine inoculations, at weeks 16 and 24. The still-blinded data for 180 trial participants, enrolled at a ratio of two vaccine recipients for each placebo, reveal no safety concerns. These results are very similar to those observed in the Phase 1 trial. The trial, designated HVTN 205, is being conducted by the HIV Vaccine Trials Network (HVTN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health.
Of particular interest are assay results measuring vaccine-induced cellular (T-cell) immune responses, which are available for 128 of the participants. These tests revealed cellular immune response rates similar to those observed in the Phase 1 trial. Additional testing is ongoing to measure antibody responses and to further characterize cellular immune responses. Data will continue to be accumulated as the trial is completed.
"The high level of safety was expected" said Dr. Harriet Robinson, Chief Scientific Officer of GeoVax, "because of the excellent tolerability of recombinant DNA and recombinant MVA vaccine vectors in humans in our, as well as other prior trials. The apparent reproducibility of vaccine immunogenicity is very encouraging. The immunogenicity data not only indicate that our vaccine products are functioning as designed but also demonstrate the capabilities of the central HVTN laboratory whose scientists have developed and validated the assays that are so critical to clinical vaccine testing."
Zap making big move into China
By Loralee Stevens, Business Journal Staff Reporter
http://www.northbaybusinessjournal.com/27450/zap-making-big-move-into-china/
Jonway purchase would bring access to enormous Zheijang production plant
Zap Jonway will manufacture and sell both gasoline and electric vehicles.
SANTA ROSA – Zap’s electric vehicles will most likely go into high-volume production in China.
The company’s pending 51 percent stake in Jonway Automobiles in the Zheijang Province of China will bring major changes to the 50-employee Santa Rosa pioneer of Zero Air Pollution vehicles, which got its start in Sonoma County in the 1970s.
Zap Jonway, as the new company will be called when the deal is finalized, will manufacture and sell both gasoline and electric vehicles.
“Incentives in China are very aggressive,” said Priscilla Lu of Cathaya Capital, one of Zap’s largest investors and member of its board of directors. “China wants to be the world leader in electric vehicles.”
Zap CEO celebrates with its new manufacturing arm Zap Jonway in China
“The government subsidizes electric vehicles at about $9,000, and large cities like Beijing and Shanghai add another $9,000. That’s over three quarters of the cost, and the subsidies go to the manufacturer, not the car buyer,” she said.
Utilizing efficiencies of scale, manufacturing electric vehicles alongside gasoline vehicles will enable Zap Jonway to offer the most competitive prices in the market, she said.
A new co-CEO, Alex Wang, is expected to expand the market from China to the rest of the world, according to a release from Zap.
Jonway already sells an electric SUV, manufactured in its ISO 9000-certified, 3.6 million-square-foot plant in the city of Sanmen. The plant will be expanded and enhanced to manufacture Zap vehicles.
“The plant is the size of the Nummi plant in full production,” said Zap CEO Steven Schneider. “Owning 51 percent of an operation like that means that our future plans can be implemented very quickly, using only a fraction of the plant’s capacity.”
The company has partnerships in Korea and soon will announce other Asian partners, Mr. Schneider said.
“The Asian market is very, very interested in electric vehicles.”
Zap will still do assembly work on vehicles it produces for the U.S. government. It’s a finalist for contracts to refit U.S. Postal Service trucks, although just how many in the 120,000 fleet will be awarded to Zap is not known, he said.
Zap got its start manufacturing electric scooters during the 1970s. The company has grown its product line to include sedans, roadsters, vans, trucks and recreational vehicles. Zap stock is traded over the counter under ZAAP.
Zap’s activities in China – which include a deal with Shanghai officials to provide charging stations, battery swap facilities and maintenance depots for the commercial district and a pilot program to add Zap vehicles to the district’s bus, government and taxi fleets – caused quite a buzz at the recent Bay Area Council meeting.
Council president Jim Wunderman called it “a major milestone for the Bay Area’s electric vehicle industry.”
Share and Enjoy:
GeoVax Labs, Inc. Strategy Supported by Encouraging Results of European Therapeutic HIV/AIDS Vaccine Trial
http://ih.advfn.com/p.php?pid=nmona&article=45426410
Nov 29, 2010 08:00:00 (ET)
ATLANTA, Nov. 29, 2010 /PRNewswire via COMTEX/ -- GeoVax Labs, Inc. (GOVX, Trade ) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), announced it was pleased to learn of the partial success observed in the recently completed Phase 2b trial of a therapeutic HIV/AIDS vaccine produced by Bionor Immuno AS of Oslo, Norway. Bionor reported success in reducing viral load (reduction in HIV virus in the blood stream) in individuals who were vaccinated then weaned from anti-retroviral therapy (ART). HIV replication was reduced as the result of the vaccine recipient's immune system.
Robert McNally, Ph.D., Chief Executive Officer and President stated, "In the war against HIV/AIDS, vaccines have two unmet objectives. First of all, the fight continues to design vaccines which will prevent an individual from being infected by HIV and, for those individuals already infected with HIV, the development of a therapeutic vaccine to supplement the existing anti-retroviral drug regimens. Earlier this year Argos Therapeutics presented data from their Phase 2 clinical trial designed to test a vaccine based on an individualized medicine approach. They observed a greater than 20-fold reduction of HIV replication in approximately 65% of individuals responding to the vaccine. The Bionor vaccine reduced HIV replication by approximately 5-fold in the population of treated individuals. This announcement gives encouragement to all participants in the HIV/AIDS vaccine effort. Ultimately, success for a therapeutic vaccine will be achieved."
The Bionor product, designated Vacc-4x, consists of four synthetic peptides derived from a major HIV structural protein. The vaccine is injected in combination with a human cytokine (Granulocyte-macrophage colony stimulating factor-GM-CSF) which serves as an adjuvant to augment immune responses. The vaccine is thought to function by stimulating the expansion of both CD4+ (helper) and CD8+ (killer) T cells. GeoVax HIV/AIDS vaccine products are likewise designed to induce T cell based immune responses, but unlike the Bionor product, our vaccines also induce antibody responses to reduce the rate of virus spread in treated individuals.
"Within the two main areas of focus for HIV/AIDS vaccines - preventative and therapeutic - GeoVax continues to make progress," stated Dr. McNally. "Our preventative vaccine candidate is being tested in a Phase 2a trial sponsored by the Division of AIDS (National Institutes of Health) and conducted by the HIV Vaccine Trials Network (HVTN). Assessment of the therapeutic potential of GeoVax's vaccine is being tested in an ongoing Phase 1 trial which will include ART interruption; a design feature similar to both the Argos and Bionor trials. Active recruitment among recently infected HIV individuals is underway for our Phase 1 therapeutic trial."
About GeoVax Labs, Inc.
Zap charging its way in to China's EV market
Andrew S. Ross
San Francisco Chronicle November 23, 2010 04:00 AM Copyright San Francisco Chronicle. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Tuesday, November 23, 2010
--------------------------------------------------------------------------------
Print E-mail del.icio.us
Digg
Technorati
Reddit
LinkedIn
Facebook Slashdot
Fark
Newsvine
Google Bookmarks
Twitter
Yahoo! Buzz
Share Comments (5)
Georgia (default)
Verdana
Times New Roman
ArialFont | Size:
--------------------------------------------------------------------------------
0 Zap / ZAP
This is an example of the vehicle Zap Jonway is developing for China's EV market.
--------------------------------------------------------------------------------
Images
View Larger Images
--------------------------------------------------------------------------------
Bottom Line
Expert networks: Advantage or arrest a fine line 11.25.10
New Squaw Valley owners plan $50 million upgrades 11.24.10
Zap charging its way in to China's EV market 11.23.10
New Golden State Warriors owners seek turnaround 11.21.10
More Bottom Line »
--------------------------------------------------------------------------------
Chalk up another one for Zap in the race to enter China's electric car market
The small Santa Rosa EV maker has just signed a deal with Shanghai officials to provide charging stations, battery swap facilities and maintenance depots for the city's commercial Yangpu district.
Zap will also develop a pilot Electric Vehicle Eco-City program involving the use of Zap vehicles in Yangpu's bus, taxi and government fleets. Sales and marketing offices and R&D centers will be located there.
CEO Steven Schneider was traveling on business and not available for comment Monday, but Jim Wunderman, president of the Bay Area Council, called it "a major milestone for the Bay Area's electric vehicle industry."
Earlier this year, Zap acquired a 51 percent stake in Jonway Automobile, a Chinese car and motorcycle manufacturer, in a $120 million deal approved by the Chinese government in October.
The combined company, called Zap Jonway, is planning to ramp up production next year, primarily at a 3.6 million-square-foot plant in China's eastern coastal province of Zhejiang. Other assets acquired by Zap include 500 Jonway dealerships across the country.
Connections pay: The deal was first broached during Gov. Arnold Schwarzenegger's trade mission to Asia in September, which included a stop in Shanghai, where he was accompanied by Bay Area Council executives. The council's recently opened Shanghai office introduced Zap executives to the right people there and helped negotiate the deal.
"This is a great example of what connecting California innovators with governments and businesses around the world can do," Schwarzenegger said. "As a direct result, Zap is breaking barriers in exporting clean technology from California to China."
It should also make for breakthroughs on Zap's balance sheet. Before the Jonway tie-in, sales amounted to $4.1 million in 2009 and the 15-year-old company has yet to return a profit. But business had already been picking up for its three- and four-wheel vans, pickups, taxis, sedans and SUVs. Customers in the past year include UPS, U.S. military bases and companies in Malaysia and South Korea.
According to its latest five-year plan, China aims to have 1 million hybrids and EVs on the road by 2015, and is investing upward of $15 billion in the sector over the next 10 years. While some estimates are more conservative, global bank HSBC sees China's share of the world's EV market vaulting from 2.7 percent this year to 35 percent by 2020.
That may be one reason why HSBC invested $125 million and took a 10 percent stake in Better Place, Palo Alto's EV company, which this year struck a development with Chery Automobile, China's largest domestic car dealer.
Needing review: How come, a number of readers wanted to know, I didn't mention the "boycott Target" movement in Friday's item about a Target store opening in San Francisco's Metreon?
The movement was triggered by the Minneapolis company's $150,000 donation to a group that ran ads supporting Minnesota gubernatorial candidate Tom Emmer, an avowed opponent of gay marriage.
Folks inside Target were none too pleased, either, it seems. While "the intent" of the contribution "was to support economic growth and job creation," CEO Gregg Steinhafel wrote to employees in August, "I realize our decision affected many of you in a way I did not anticipate, and for that I am genuinely sorry."
As a result, he added, the company will "review its decision-making process for financial contributions in the public policy arena."
It's difficult to assess the boycott's impact, although it seemed to have little bearing on the San Francisco Redevelopment Agency's 10-member board, which unanimously approved the project last week.
"None of the public speakers raised it," said Amy Neches, the agency's project planning and development manager. "One of the commissioners alluded to it in his comments, but did not pursue it."
An agency memo noted that in 2009 Target gave approximately $1 million to San Francisco nonprofits, including the San Francisco AIDS Foundation.
Blogging at sfgate.com/columns/bottomline. Facebook page at sfg.ly/doACKM. Tweeting @andrewsross. E-mail bottomline@sfchronicle.com.
This article appeared on page D - 1 of the San Francisco Chronicle
--------------------------------------------------------------------------------
Print E-mail del.icio.us
Digg
Technorati
Reddit
LinkedIn
Facebook Slashdot
Fark
Newsvine
Google Bookmarks
Twitter
Yahoo! Buzz
Share Buzz up! 0
Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2010/11/22/BUA11GFQ7O.DTL#ixzz16NwgK4Lt
China strengthens ties to Zap electric carmaker
By ROBERT DIGITALE
THE PRESS DEMOCRAT
Published: Tuesday, November 23, 2010 at 5:26 p.m.
Last Modified: Tuesday, November 23, 2010 at 5:26 p.m.
( page of 2 )
Santa Rosa’s electric vehicle retailer Zap has signed a memorandum of understanding with Chinese officials to promote electric cars on the streets of Shanghai.
The company separately announced that it has completed a $10 million down payment for a majority share in Chinese car maker Jonway Automotive. The payment is part of a $29 million purchase agreement first announced in July.
The two developments are part of Zap’s efforts to become a manufacturer and retailer of electric vehicles in China, now the world’s largest auto market.
The memorandum is “the first big deal of its kind,” the result of growing ties between business and government leaders from the Bay Area and Shanghai regions, said Jim Wunderman, president and CEO of the Bay Area Council, a business advocacy group. It was fostered in part by a state delegation that Gov. Arnold Schwarzenegger and the Council led to China in September.
The deal, Wunderman said, signals that both Zap and local Chinese officials understand that neither party can by itself build the charging and battery-swap stations needed to make electric vehicles a practical means of transportation in Yangpu, a district of Shanghai.
“Whether you’re building electric vehicles in the Bay Area or China, it’s going to require a public/private partnership to get it done,” Wunderman said.
For the nine months ending Sept. 30, Zap reported a net loss of $7.3 million, compared to $7.5 million a year earlier. The company has posted one profitable year in its 16-year history.
The memorandum, signed last week in San Francisco by Yangpu party secretary Chen Yin, does not give Zap the right to exclusive sales, said Zap Board Chairwoman Priscilla Lu. But in a country where relationships are key, she said, “this signing of the agreement shows his commitment and trust of the company.”
Production of Zap/Jonway electric vehicles is scheduled to begin in China in the second quarter of 2011, she said.
Previous Page12
US: ZAP to provide EV services in Yangpu, Shanghai
By: just-auto.com editorial team | 23 November 2010
Santa Rosa-based EV maker ZAP has signed a deal with Shanghai officials to provide charging stations, battery swap facilities and maintenance depots for the city's commercial Yangpu district.
Zap will also develop a pilot electric vehicle eco-city programne involving the use of its vehicles in Yangpu's bus, taxi and government fleets and sales and marketing offices and R&D centres will be located there, the San Francisco Chronicle reported.
Jim Wunderman, president of the Bay Area Council, called it "a major milestone for the Bay Area's electric vehicle industry".
Earlier this year, Zap acquired a 51% stake in Jonway Automobile, a Chinese car and motorcycle manufacturer, in a US$120m deal approved by the Chinese government in October.
The combined company, called Zap Jonway, is planning to ramp up production next year, primarily at a 3.6m sq ft plant in China's eastern coastal province of Zhejiang. Other assets acquired by Zap include 500 Jonway dealerships across the country.
The report noted China aims to have 1m hybrids and EVs on the road by 2015, and is investing upward of $15bn in the sector over the next 10 years. While some estimates are more conservative, global bank HSBC sees China's share of the world's EV market vaulting from 2.7% this year to 35% by 2020
ZAP is the first American company to have controlling interest in a Chinese automotive manufacturer, with a jump on the electric vehicle market.
With its headquarters in California, ZAP Electric Vehicles made business history last month when it announced that it had gained approval from the Chinese government to acquire Jonway Automotive, becoming the first American company to have controlling interest in a Chinese automotive manufacturer. With this powerful foothold into the Chinese market, ZAP Electric Vehicles is revolutionizing the automotive market by delivering a variety of affordable electric cars to the market. To detail the recent developments and the difference in business climate for clean tech companies in China versus California and the United States, TPR/MIR is pleased to present the following exclusive interview with ZAP Electric Vehicles CEO Steve Schneider.
Published Monday November 1, 2010
2557 words
Excerpt:
To access this story
If you already have an archives account, enter your username and password to view this story. If you don't, you may sign up for one below.
Steve Schneider
ZAP has received some very significant news from the Chinese Government; an approval that could position your company as a pacific rim leader in the Electric Vehicle marketplace.
Today was a very significant day for ZAP. It’s something we have been working on for a long time. It was something that all the experts—political, media, and otherwise—said couldn’t be done, which is an American company having a controlling interest in a Chinese automobile manufacturing company. As of today, the Chinese government has approved the merger between ZAP and Jonway. It is really an acquisition. Today we officially own 51 percent of Jonway Automobile. We are following that up with another 49 percent acquisition. We are doing it in two stages because of the way we were paying for it. The significance wasn’t the payment, the significance was getting the Chinese government to approve the controlling interest, and we did it in what is a first in China.
How did Zap actually win China’s approval to acquire control of Jonway? What about your merger was compelling?
Any thoughts on the weeks ahead for zap?
ZAP Extends Rally Higher after Updating Shareholders
ZAP (ZAAP, Free Analysis), a provider of fully-electric and other advanced technology vehicles, has rallied more than 50% over the past five days after providing an update on its 51% acquisition of Jonway Automobile, a debt-free, cash flow positive and self-financed company. Investors are hoping that the acquisition will help the company grow its revenues and generate shareholder value.
Last quarter, the automobile company generated revenues of $985,000 and a net loss of $1,888,000, or 2 cents per share, with 109,611,000 shares outstanding. Meanwhile, the firm faces a slight deficit between current assets and current liabilities, but its total assets are significantly higher with no long-term debt.
hope you found your entry point
ZAP Merger With One Of Worlds Largest Motorcycle Manufacturer; MDB Capital Analyst Shares His Thoughts On The Deal
ShareretweetEmailPrintCompanies:Baidu, Inc.Evergreen Solar Inc.General Electric Co. Related Quotes
Symbol Price Change
BIDU 108.53 +1.61
ESLR 0.82 +0.01
GE 16.15 +0.34
MXWL 15.47 +0.67
{"s" : "bidu,eslr,ge,mxwl","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} On Thursday November 4, 2010, 11:17 am EDT
67 WALL STREET, New York - November 4, 2010 - The Wall Street Transcript has just published its Alternative Energy & Utilities Report offering a timely review of the sector to serious investors and industry executives. This Special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Climate Change Regulatory and Political Uncertainty - New Dividend Tax Rate Legislation - Uptick in M&A - Growth for Pure-Play Alternative Energy Companies
Companies include: A123 (AONE); Ener1 (HEV); ADA-ES (ADES); AEP (AEP); Agrium (AGU); Allegheny Energy (AYE); Alliant Energy (LNT); and many more.
In the following brief excerpt from the Alternative Energy Report, expert analysts discuss the outlook for the sector and for investors.
Jon Hickman joined MDB Capital Group LLC in 2005 to cover emerging-growth companies in the technology, media and health care sectors. Prior to MDB, he was an Equity Analyst at Security Research Associates and Halpern Capital, where he covered technology and life science companies. Mr. Hickman began his career in 1980, working with Bank of America's trust department in San Francisco, where he analyzed private companies. He then spent 16 years managing institutional growth-oriented money at Wells Capital Management and later at Jurika & Voyles. Mr. Hickman has a B.A. in chemistry and an MBA in finance from Brigham Young University.
TWST: Would you tell us a bit about ZAP and their merger this summer with Jonway Auto Group.
Mr. Hickman: ZAP is a very interesting little company. It is headquartered out of Santa Rosa, Calif. They have actually been around quite a while. Right now they can still make a claim that they've produced more electric vehicles than anybody else in the United States. These vehicles have been mostly electric scooters or electric bikes. More recently the company moved into a three-wheeled, utility-type vehicle, kind of a funny-shaped, three-wheeled vehicle. By doing a three-wheeled vehicle, you don't have to meet all the safety standards that a normal highway-speed vehicle has to meet. So ZAP was able to get around these standards and produce a relatively cheap vehicle that has enjoyed some pretty good acceptance around the country. These small electric vehicles were just powered with normal lead-acid batteries. You could get a lithium-ion upgrade, but it changed the price of the vehicle quite dramatically and most people didn't choose that option.
Most recently, ZAP has been involved with a Chinese auto manufacturer and has been producing a sturdier and more utilitarian vehicle with four wheels that looks much more like a car or van than their previous electric vehicle. They have been importing that vehicle from China, putting the finishing touches on here in the United States, in Santa Rosa, and then distributing from there. This car again is not meant as a highway-speed vehicle; it has a 35-mile-an-hour top speed on it - again, so you don't have to meet all the safety requirements - but the car is much sturdier and, I don't know, more normal-looking. These vehicles have been well received in spite of a pretty poor economy in the last couple of years. So because ZAP had this long history and fairly successful electric vehicle experience here in the United States, they were approached by a French fund that only invests in China. This fund, the Cathay Fund, made a fairly significant equity investment in ZAP last year with the goal of using ZAP's experience to get into the Chinese electric vehicle market. Using its Chinese contacts, the people at the Cathay Fund introduced ZAP to the Jonway, a Chinese vehicle manufacturer.
Jonway is one of the largest, if not the largest, motorcycle manufacturers in the world, and they have been moving into electric vehicles based on their motorcycle history and experience. So now they have taken ZAP's know-how in taking a basic Chinese gas vehicle and modifying it into an electric car. ZAP knows how to do that really well, and so they have married that experience with Jonway's manufacturing capacities. Earlier this past summer, ZAP actually acquired 51% of Jonway's automobile division. The merger actually makes quite a bit of sense, as Jonway auto products will provide ZAP with an instantaneous revenue stream that's much, much larger than what ZAP has been experiencing before. And ZAP should be able to be cash flow positive based on this new revenue level.
TWST: What is your number one stock pick and why?
Mr. Hickman: The one that's obviously performing with revenues, generating rapid revenue growth and accelerating bottom-line earnings is Satcon. The stock has actually moved up quite nicely along with the good news. I think it's trading around the $4 level right now. It's down a little bit today because of the capital raise announcement, but kind of the low $4. I would argue that at this level, the stock is still a very solid buy. I wouldn't be surprised if somebody came along and they wanted to get into the inverter business and snap them up. Of the others that we've talked about, Altairnano has its partnership now, so they are 51% owned by Canon. So that makes that kind of less attractive. I'm pretty interested in Quantum. With their Fisker contract, the potential for the post office and other initiatives in alternative energy, solar power, there's a possibility that calendar 2011 could be a very, very good year for Quantum. I think that's the one I would keep my eye on.
The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This Special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .
The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.
For Information on subscribing to The Wall Street Transcript, please call 800/246-7673
Follow Yahoo! Finance on Twitter; become a fan on Facebook.
Related Headlines
Stocks Surge On Much Stronger Philly Fed Numbers - at Barrons.com
U.S. approves GE acquisition of diagnostic company - at Reuters
UPDATE 1-US approves GE acquisition of diagnostic company - at Reuters
GM Stock: Whoa. Check out the Monster Volume - at The Wall Street Journal
InPlay: Baidu.com continues to display opening relative weakness as it dips down into yesterday's highs - Briefing.com
Related Blog Headlines
Lightning Round OT: Baidu, Best Buy and More - at CNBC
China Breaks Airbus-Boeing Monopoly - Zacks
St. Jude & ZONARE in Imaging Tie-up - Zacks
Illinois Tool Provides 4Q Guidance - Zacks
Siemens Underperforms EPS
:) Thanks Sunb.. heading out to do some hunting,That is if these old bones can get up in that tree.. Be back middle of next week..Hold down the fort..
:) Have a great weekend ....
GOFOR....
Thank you, for helping get that point across.
Thank you, Now we just need zap to decide, it is time to show a profit ...
With all respect DF .. I think you are missing the point ..Which is, this seems to be a new outlet .. Meaning new eyes are looking at MOP for possibly the first time .. Old news to us on this board, Is new to alot of the public.
Keep in mind the world does not revolve around IHUB
I'm not sure.
But I believe, we all realize that MOP is becoming more of a common name in the industry . All good for us !
Absorbent product aids Gulf spill cleanup
Nov 12, 2010 2:34 PM, By Michael Keating (michael.keating@penton.com)
http://govpro.com/public_works/content/mop-oil-absorbent-20101112/
Gulf Breeze, Fla., relied on MOP (Maximum Oil Pickup) 201 bulk loose sorbent to absorb oil from the 2010 Gulf oil spill. The city distributed the sorbent to waterfront landowners to help prevent and minimize spill damages to beachfront property.
Bags of MOP (Maximum Oil Pickup) 201 bulk loose sorbent from MOP Environmental Solutions.
The sorbent joins beach cleaning machines, vacuum excavators, booms and work boats in scrubbing beaches following the Gulf oil spill.
MOP 201 is an aggressive oleophilic and hydrophobic (oil-attracting and water-repelling) sorbent made from recycled and fully biodegradable materials, and is manufactured using small-scale hydroelectric green energy. Bath, N.H.-based MOP Environmental Solutions produces MOP 201.
"One container of MOP sorbent can contain up to 75,000 gallons of oil in four hours. It would take about 23,000 booms to get the same results," said MOP Environmental Solutions CEO Charles Diamond. Crews used a boat skimming process on the Gulf Spill. In the process, "boats tow nets filled with the MOP sorbent through the oil, capturing far more oil than conventional skimmers in much less time. The process is easily and inexpensively scalable by simply adding more boats and nets to the process. In just one day, hundreds of thousands of gallons of oil can be contained," Diamond said.
Responding to the Gulf oil spill is a long-term effort, said Wayne King, MOP Environmental Solutions' vice president of communication, business development and innovation. "We are increasing production in response to the Gulf Spill, which we anticipate will take up to a year or more. We are also planning on increasing demand because of our cradle-to-cradle green niche market."
According to the company, the sorbent is safe for the environment, including birds, animals, and aquatic life. The product can be used in a variety of terrain, including marshlands and beaches. It is rapidly deployed at over 150 mph using the manufacturer's MOP-Cannon and removed using the firm's MOP-Vac. MOP is applied on the surface or below water where it floats up and locks in oil, neutralizing all potential harmful effects of the spilled oil. The product recovers oil under all weather conditions. The sorbent's recovery process enables reusing of retrieved oil.
The product picks up to 30 times its own weight in oil, without absorbing water, according to the manufacturer. The sorbent restores traction on slippery surfaces. The sorbent is suited for a variety of applications and markets, including:
Direct to consumer — the sorbent captures leaks and spills from auto, RV, motorized home equipment and used cooking oils. Commercial and industrial — Manufacturers and other companies that operate machinery can find uses for the sorbent. International spill response — the sorbent minimizes damages from oil
Diversification of MOP Environmental Solutions Products Could be Key to Company’s Success, Bolster Investor Activity
http://www.otcequity.com/?p=289
Having grabbed investors attention following the Deepwater Horizon oil spill disaster in the Gulf of Mexico earlier this year MOP Environmental Solutions, Inc. (Pink Sheets: MOPN) quickly saw its fortunes turn when they received a purchase order from BP, pushing their share price from 0.08 to a 52-week high of 0.35 on June 7, the first day of trading following that announcement. Since that time shares have continued to dip and MOPN is now back down to the 0.09 range, slightly lower than its 50-day moving average of 0.1053 but better than its 200-day moving average of 0.0675.
While a favorable opinion of MOPN was recently expressed by Larry Oakley, often referred to as the “Elder Statesman of Emerging Growth Investment Writers,” his insistence that potential investors view Mop Environmental “from the posture of someone who has two intents: (A) To realize the type of appreciation potential that you would have enjoyed if you had invested in Microsoft, for example, when it was just starting as a public company; & (B) To be a part of & a backer of a technology that has the probability to save countless birds & animals from the ravages of oil spills; clean up not only Earth’s atmosphere, but a great many aspects of our industrial facilities” might be a bit much.
That being said, there are certainly a number of attractive qualities presented by MOPN that could turn the stock into a financial reward for investors. The most attractive of these qualities is in the fact that their oil recovery products work and they that claim has been backed by a number of testimonials from BP, USA Fuel Service LLC and others. Not to be overlooked, the company also points out that “MOP sorbents are the only oil spill remediation products on the planet that are green from “cradle-to-cradle” being manufactured with green hydro-electric power, and all natural materials that are 100% Biodegradable and 100% Recycled.” When it comes to cleaning up an environmental disaster the “greener” the process the more likely it will be received well.
The increased demand for MOP Environmental Solutions products following the Gulf oil spill actually put the company in a position where they needed to secure financial services so that they may continue to fill orders. MOPN opted to secure Bibby Financial Services for that need and according to Diamond the move would allow them to offer “better terms to capture large orders from large customer accounts.”
One of those larger accounts appeared to have been landed as the company stated last month that “one of the world’s largest oil companies, whose name we are unable to disclose without violation of their press release disclosure terms, has accepted MOP Environmental Solutions, as a vendor, with issuance of vendor number, internal contact hot line, and the confirmation of its vendor status.” While details surrounding that oil company remain vague it certainly has Diamond excited as he has expressed supreme optimism for what lies ahead. The CEO said the company now anticipates orders for spill kits designed for oil cargo vessels and with U.S. Federal Regulations mandating all oil carrying vessels in U.S. Waters to carry oil spill cleanup equipment the financial benefit for MOPN could be significant.
This growth has led MOPN to form strategic alliances with a pair of companies that would make meeting the demands possible. The company has turned to Leigh Fibers to help produce the sorbent materials while Global Sales Co. has the production capacity for booms five times greater than MOP.
Adding to the value of MOPN is the fact their breakthrough absorbent material MOP (Maximum Oil Pickup) is patented and according to the company clean oil can be recovered from the oil-saturated sorbent, making it possible to extract, salvage, and re-use up to 95% of the absorbed oil. That oil is free from contamination and the remaining 5% MOP material can be burned to recover 100% of the available energy.
Topping off all the positives for MOPN is their posted financial statements back in late July in which they revealed they had over $90,000 in cash on hand and total assets nearing $250,000 for the period ending June 30, 2010. In the month that followed that June 30, 2010 statement MOPN said they had about $200,000 in available cash and accounts receivable of over $165,000.
Despite all of the positive aspects of MOP Environmental Solutions the company’s stock remains in the 0.08-0.10 range and that should raise some red flags.
What MOPN appears to be lacking is any kind of presence in the consumer market. The company has insisted MOP is ideal for absorbing everything from gasoline, diesel fuel, motor oil and viscosity enhancers to jet fuel, ethyl alcohol and methyl ethyl and can be used in oil and gas production, petroleum transportation, gas transmission, health care facilities, rail transportation, service stations, airports and “many other industrial and service applications” yet it hasn’t found itself on the shelves of a major store.
Failing to reach the direct to consumer and the commercial industrial markets could have devastating effects on the company and it is difficult to see how the company is addressing the issue.
Much was being made about the opinion of Oakley and while he stated “the long-term benefits I see are amazing” and the product could “practically save this planet for our children’s children” there remains plenty of doubt in the minds of many investors. Oakley does mention that his opinion piece on MOP was without cost to the company but that he was “sufficiently impressed to invite Charles Diamond to have his company come aboard as a client” on his site. Naturally Diamond agreed and Oakley will now be preparing a Research Report in the next two weeks, a service that dos come with a charge.
While landing orders for emergency response projects and government deals will get MOPN some attention the company will need to rely on the consumer and commercial industrial markets to generate their financial rewards. If they are honest in their efforts to grow their products this could be a great time to investigate the stock but failing to take off following the BP oil disaster could be an ominous sign as they may not ever see a better opportunity to prove their products worth.
MOPN Chart:
Small-Cap Research on Accuride Corp. and ZAP -- Vehicle Industry Back on Its Feet
Zap (BB) (OTCBB:ZAAP)
Intraday Stock Chart
Today : Friday 12 November 2010
www.wallstreetequityresearch.com gives shareholders valuable insight on vehicle industry stocks Accuride Corp. (OTCBB: ACUZ) and ZAP (OTCBB: ZAAP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.
The Vehicle industry has been on the rise recently as consumers are returning to sales lots to purchase new vehicles that they had put off during the recession. Some of the larger companies that posted catastrophic numbers during the down economy have bounced back to post small losses or even profits in some cases. U.S. auto sales have risen 11 percent in the first ten months of 2010.
www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports vehicle industry; traders looking for analyst opinions on Accuride Corp., ZAP and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.
Sales in emerging markets like India and China have also been positive. Auto sales for the month of October increased by 38 percent year over year in India, while China posted vehicles sales up 25 percent when compared over the same period. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the vehicle industry in today's economic environment.
Increased interest in electric cars has also been a boon to those offering electric models, and some companies in the industry have been expanding operations and signing partnership deals to further their production. One such company is ZAP. The company purchased a controlling interest in a Chinese auto manufacturing company earlier this year in order to expand operations in China, and it has also recently signed a development deal with Remy Electric Motors. Traders can have complimentary access to today's complete research report on ZAP by signing up at http://wallstreetequityresearch.com/November122010ZAP(ZAAP.OB)121110.php.
With the economy recovering on a whole, freight delivery has increased, which has led to increased freight rates. As companies involved in delivering freight have begun to see increases in sales, they have started to update their aging fleets. Suppliers and manufacturers of vehicle parts such as Accuride Corp. have benefitted from this, and have recently posted positive quarterly earnings. Traders can get direct and free access to today's full report on Accuride Corp. by signing up at http://wallstreetequityresearch.com/November122010AccurideCorp.(ACUZ.OB)121110.php.
Registration Effectiveness Orders Issued By The SEC
Nov 9, 2010 09:28:20 (ET)
The following table includes registration statements and post-effective amendments that were declared effective by the Securities and Exchange Commission on the most recently completed business day.
The Securities Act of 1933 requires companies offering securities to file a registration statement with the SEC that discloses material facts for investors. The SEC staff reviews registration statements and declares them "effective" if companies satisfy the disclosure rules.
REGISTRATIONS EFFECTIVE AS OF November 8, 2010
IPO:
GeoVax Labs Inc. (GOVX)
File Number: 333-165828
Date of Original Registration: 3/31/10
Form Type: S-1
Securities Registered: Up to $40,000,000 units, each
consisting of one share of common stock and warrants to
purchase 0.20 shares of common stock
Selling Holder: No.
S-4 s and F-4 s:
Chuo Mitsui Trust Holdings Inc.
File Number: 333-170434
Date of Original Registration: 11/8/10
Form Type: S-4
Securities Registered: Up to 396,848,191 shares of Common Stock
Selling Holder: No
Terra Nova Royalty Corp. (TTT)
File Number: 333-169819
Date of Original Registration: 10/7/10
Form Type: S-4
Securities Registered: 25,001,089 Common shares with par value
Selling Holder: No.
MIXED SECURITIES:
Gentiva Health Services Inc. (GITV)
File Number: 333-170072
Date of Original Registration: 10/21/10
Form Type: S-3
Securities Registered: $300,000,000 Debt Securities, Preferred
Stock, Common Stock and Warrants
Selling Holder: No.
(END) Dow Jones Newswires
November 09, 2010 09:28 ET (14:28 GMT)
Yes I know, thank you for the reply
Picasa Web Albums [picasaweb-noreply@google.com]
Recent Uploads
Wayne added a photo to MOP Newsfeed
Nov 9, 2010 9:31:46 AM
GeoVax Labs, Inc. Announces Nine Month 2010 Financial Results
November 9, 2010 9:00 AM ET
GeoVax Labs, Inc. Announces Nine Month 2010 Financial Results
PR Newswire
ATLANTA, Nov. 9, 2010
ATLANTA, Nov. 9, 2010 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTCQB / OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical firm (the "Company" or "GeoVax") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results for the three and nine months ended September 30, 2010.
GeoVax reported a net loss of $644,666 ($0.04 per share) for the three months ended September 30, 2010, compared to $230,815 ($0.02 per share) for the same period in 2009. For the nine months ended September 30, 2010, the Company's net loss was $2,268,544 ($0.14 per share) as compared to $2,440,977 ($0.16 per share) for the same period in 2009.
Net losses were partially offset by revenues related to the Company's grant from the NIH in support of its HIV/AIDS vaccine development activities; such revenues were $1,163,288 and $4,239,017 for the three month and nine month periods of 2010, respectively, as compared to $1,808,551 and $3,271,506 for the three month and nine month periods of 2009, respectively.
As of September 30, 2010, the Company reported cash balances totaling $1,426,342, as compared to $3,515,784 at December 31, 2009.
Dr. Robert McNally, PhD, GeoVax's President and CEO, commented, "GeoVax continued to make solid progress during the third quarter of 2010. Our Phase 2a clinical trial for the preventative version of our HIV/AIDS vaccine is on schedule, with full patient enrollment expected by the end of 2010 and trial completion during 2011. Our Phase 1 clinical trial for the therapeutic version of our vaccine, for treatment of HIV-infected individuals, is also progressing, as we continue to actively recruit patients for this groundbreaking trial. We have screened numerous individuals for meeting the stringent enrollment criteria for participation in this trial and have selected a handful of candidates for continued evaluation. Once a candidate has achieved six months of stable viral control while on drug treatment, they can then enter the trial and receive the first vaccination. Our pipeline product, which uses an adjuvant to boost the immune system response, is also moving rapidly through the development process. We have completed preliminary discussions with the FDA and plan to submit an Investigational New Drug (IND) application in early 2011, with the intention of beginning a Phase 1 human clinical trial by the middle of 2011. We are very excited about the prospects for this program, as the preclinical data are very compelling."
Dr. McNally continued, "Our primary focus is on accelerating our clinical programs with the objective of generating the necessary data to demonstrate the efficacy in humans of our vaccine candidates. To that end, we are also directing our efforts towards ensuring we have the financial resources available to achieve our objectives and make the appropriate commitments to our programs. The federal government continues to be a strong supporter of our efforts, through significant support provided by the HIV Vaccine Trials Network (HVTN), funding through our Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the NIH, and through the recently awarded Qualified Therapeutic Discovery Project (QTDP) grant. We intend to supplement these funds through our own equity financing activities."
Summarized financial information is presented below. Further information concerning the Company's financial position and results of operations is included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
November 8th, 2010 04:35am
Business cluster sets investor summit
By Loralee Stevens, Business Journal Staff Reporter
http://www.northbaybusinessjournal.com/26650/business-cluster-sets-investor-summit/print/ http://www.northbaybusinessjournal.com/26650/business-cluster-sets-investor-summit/print/Print Friendly
Keynote by Raydiance founder Schuler; cars, cab and startup pitches
http://www.northbaybusinessjournal.com/wp-content/uploads/68-Bizzarrini_CAR.jpg http://www.northbaybusinessjournal.com/wp-content/uploads/68-Bizzarrini_CAR.jpg
Fancy cars and high-end cabernet will be part of the North Bay Investment Summit.
ROHNERT PARK – High-end cabernet and cars will be sideshows at the second North Bay Investor Summit, an event its sponsors hope will attract capital to aspiring startups in the area.
About 200 accredited investors – confirmed by the Securities Exchange Commission as having a net worth of at least $1 million not including homes – will be converging on Rohnert Park this Wednesday as invited guests of the fanciest Investor Forum ever planned for the region.
“We’re gathering together a demographic that you don’t often find in one place at a time,” said Michael Newell, executive director of the Sonoma Mountain Business Cluster, an incubator at the Sonoma Mountain Village.
The Sonoma Mountain Business Cluster and the North Bay Angels and Keiretsu Forum investment groups are producing the event with sponsorship from Silicon Valley Bank and Moss Adams.
Barry Schuler, CEO of Raydiance in Petaluma and former CEO of AOL, will be the keynote speaker, and 10 aspiring startups, most from the North Bay, will vie for attention with an eye-popping array of high-end automobiles.
Tesla with a test-drive model, Lamborghini, Mercedes Gullwing, Fantasy Junction brokers and ClubSportiva are among the automotive sponsors.ZAP Electric Motors will have its X-Prize entrant there
And what goes as well with beautiful cars but great cabernets from five of the best North Bay wine makers? Our intent is to showcase the area as an innovation center as well as a wonderful place to live and work,” said Dr. Newell.
The business cluster was recently named an Innovation Hub by the state Business, Transportation and Housing Agency, one of six in the state.
“Now it’s up to us to bring in venture capital, which is the best way to launch a successful small business and bring jobs to the area. We want this summit to change people’s perception of the North Bay, especially people from other business areas like Silicon Valley,” said Dr. Newell.
OTC ADVISORS, LLC: Huge Alert On: (OTCBB:GOVX)
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus - that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.
http://www.tmcnet.com/usubmit/2010/11/04/5115760.htm
News Today: ATLANTA, Nov. 4, 2010 GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the high number of applicants.
The QTDP program was created by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. It was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries. QTDP grants or tax credits are awarded to companies with fewer than 250 employees for projects related to the treatment or prevention of diseases through the conduct of pre-clinical or clinical studies The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services. Among the determining factors used by the Secretary in allocating funds were those projects that show potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of healthcare costs. Also taken into consideration were the potential for projects to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in the fields of life, biological and medical sciences.
"We are delighted to be the beneficiary of this grant at the maximum level available," said President and CEO Robert T. McNally, PhD. "This grant was allocated following favorable federal review of our project submission, which we believe reflects the potential of our HIV/AIDS vaccine program. These funds and other grant sources continue to support GeoVax's ongoing clinical programs." About OTC-ADVISORS.COM OTC-ADVISORS.COM is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTC-ADVISORS. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
GeoVax Awarded Federal Grant Under the Qualifying
http://www.prnewswire.com/news-releases/geovax-awarded-federal-grant-under-the-qualifying-therapeutic-discovery-project-program-106685598.html
Therapeutic Discovery Project Program
ATLANTA, Nov. 4, 2010 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the high number of applicants.
The QTDP program was created by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. It was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries. QTDP grants or tax credits are awarded to companies with fewer than 250 employees for projects related to the treatment or prevention of diseases through the conduct of pre-clinical or clinical studies
The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services. Among the determining factors used by the Secretary in allocating funds were those projects that show potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of healthcare costs. Also taken into consideration were the potential for projects to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in the fields of life, biological and medical sciences.
"We are delighted to be the beneficiary of this grant at the maximum level available," said President and CEO Robert T. McNally, PhD. "This grant was allocated following favorable federal review of our project submission, which we believe reflects the potential of our HIV/AIDS vaccine program. These funds and other grant sources continue to support GeoVax's ongoing clinical programs."
this latest news looks very good for zap.. the in roads to China are not easy .. seems to be a very stabalizing factor for us.
- Current report filing (8-K)
Date : 10/29/2010 @ 1:38PM
Source : Edgar (US Regulatory)
Stock : (ZAAP)
Quote : 0.51 0.02 (4.08%) @ 3:13PM
- Current report filing (8-K)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
--------------------------------------------------------------------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 25 , 2010
--------------------------------------------------------------------------------
ZAP
(Exact name of Registrant as specified in its charter)
--------------------------------------------------------------------------------
California 001-32534 94-3210624
(State or other jurisdiction of
incorporation) (Commission
File Number) (IRS Employer
Identification Number)
501 Fourth Street
Santa Rosa, CA 95401
(Address of principal executive offices) (Zip Code)
(707) 525-8658
(Registrant’s telephone number, including area code)
Former name or former address, if changed since last report:
None
--------------------------------------------------------------------------------
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-14(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
INFORMATION TO BE INCLUDED IN THE REPORT
Section 5 Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 25, 2010, the Board of Directors (the “Board”) of ZAP (the “Company”) elected Alex (Alex) Wang as the Company’s Co-Chief Executive Officer, effective immediately. Mr. Wang will serve as Co-Chief Executive Officer with Steve Schneider, who has served as the Company’s Chief Executive Officer since June of 2002.
Mr. Wang is currently the Chief Executive officer of Zhejiang Jonway Automobile Co. Ltd. He graduated from the University of Sunderland in the United Kingdom with an undergraduate degree in business administration. Mr. Wang is also a member of Zhejiang Council and a member of the after 70’s Elite Club of Taizhou China. He has held various management positions in the Jonway Group LTD for the past five years. Mr. Wang has been able to enhance Jonway Auto’s level of modernization and internationalism.
Mr. Wang will not receive compensation from the Company for his service as Co-Chief Executive Officer.
Concurrently with the appointment of Mr. Wang to the position of Co-Chief Executive Officer, the Board appointed Mr. Wang to serve as a member of the Board of Directors. The Company has not yet determined the committees of the Board on which Mr. Wang will serve.
As previously announced by the Company, on July 2, 2010, the Company entered into an Equity Transfer Agreement for the Purchase and Transfer of Certain Equity Interest in Zhejiang Jonway Automobile Co., Ltd. (the “Equity Transfer Agreement”) with Jonway Group Co., Ltd. to acquire a 51% interest in Zhejiang Jonway Automobile Co., Ltd., a limited liability company of the People’s Republic of China (“Zhejiang”), for $29 million (the “Acquisition Transaction”). Mr. Wang is also an owner of equity interests in Zhejiang may be entitled to receive a portion of the amounts the Company will pay pursuant to the Equity Transfer Agreement if and when the Acquisition Transaction closes.
- 2 -
--------------------------------------------------------------------------------
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZAP
Date: October 29 , 2010 By: /s/ Steven M. Schneider
Steven M. Schneider
Co-Chief Executive Officer
Electric cars to get boost from Bay Area grants
Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2010/10/26/BAD81G284U.DTL#ixzz13YwysgbV
Article by GeoVax Labs CEO Featured in October 15 Issue of Genetic Engineering & Biotechnology News
CEO Robert T. McNally Assesses the Ongoing Search for an HIV Vaccine
ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).
In the article, titled "Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation Between Many Agencies," Dr. McNally reviews a set of significant advances that spotlight the current state of the HIV vaccine search. These include the finding, based on a Phase 3 trial known as RV144 and publicized by the US Military HIV Research Program, that a combination of two vaccines based on HIV strains that commonly circulate in Thailand was safe and modestly effective in preventing HIV infections. He also notes a report from the NIAID Vaccine Research Center on the discovery of three human antibodies that neutralize HIV, two of which were shown to target a broad range of HIV strains.
"The search for an HIV vaccine is an ongoing research goal that continues to challenge the top minds in the infectious disease research community. Continued funding is vital, and cooperation among various agencies may play an important role," writes Dr. McNally in the article. "As Seth Berkley and Alan Bernstein—who are president and CEO of the International AIDS Vaccine Initiative and executive director of the Global HIV Vaccine Enterprise, respectively—wrote in The New York Times in July: 'Ending HIV/AIDS urgently requires a vaccine. The evidence that a safe and effective HIV vaccine can be developed is stronger than ever.'"
To access the full text of the article, please click on the following link:
http://www.genengnews.com/gen-articles/search-for-effective-hiv-vaccine-intensifies/3451/?page=1
Hope you found an entry point . I can see China wanting zap to do well and keeping GMC OUT OF the race in Asia … of course all IMO
Other Premier Holding Plays- MOP Environmental Solutions (MOPN
http://www.wallstreetnewscast.com/news/2010/august/amsz.html
BestOfOTC.com Stocks To Watch On Monday: (LDVK, MOPN, PFTI, SOPV, ZIGO, BMRN
http://www.thefirstreporter.com/press-releases/bestofotc-com-stocks-watch-monday/
GeoVax Labs Announces Issuance of 6th Patent
US Patent #7,795,017 Addresses DNA Expression Vectors and Methods of Use
ATLANTA, Oct. 7 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has been issued via an exclusive license from Emory University, a US Patent for its "DNA expression vectors and methods of use." Issued on September 14, 2010, the patent claims cover novel vectors and novel HIV vaccine inserts.
Harriet Robinson, Chief Scientific Officer and lead inventor on the patent said, "This patent covers our pGA series of plasmids that are not only useful for delivery of DNA vaccines but have proven to have outstanding stability during large scale manufacture. pGA stands for plasmid (p) developed in Georgia (GA)."
"The patent," according to Dr. Robinson, "also covers the development of earlier forms of the DNA insert for our lead HIV/AIDS vaccine that is currently in phase 2a trials through the US HIV Vaccine Trials Network. Our HIV vaccine insert expresses non-infectious virus-like particles. These virus-like particles train the immune system to recognize the real infection, should the person become exposed. We are the only developers to achieve the expression of non-infectious virus-like particles that display the natural form of the HIV-1 envelope protein to the immune system. This unique feature is important because it is the natural form of the envelope protein that the immune system needs to recognize to efficiently tag incoming virus for destruction."
GeoVax has a patent portfolio consisting of over 20 issued and pending patents covering the Company's vaccine technology and manufacturing methods. According to GeoVax CEO, Dr. Robert McNally, "every issued patent helps protect this very promising vaccine. Currently the company has issued patents that cover the constructs for both the DNA and MVA (modified vaccinia Ankara) vaccines, the two principal vaccines that make this technology so effective and further patents are pending."
About the Patent
GeoVax's US Patent (#7795017) relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is focused on inducing an immune response against HIV.
The immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP). Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Ankara. The booster live vaccine vector includes a vaccine insert expressing the same proteins as the DNA priming vaccine.
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS). Goals include developing HIV/AIDS vaccines for global markets, overseeing manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the products forward. All preventative Phase 1 human clinical trials conducted to date have tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the Company began a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Contact
At The Investor Relations Group:
Investor Relations
James Carbonara
or
Public Relations
Janet Vasquez / Robin O'Malley
(212) 825-3210
And if they do .. this certainly will help promote the plug in stations. So EV's can at least be operational.